The Canadian Glomerulonephritis Registry will develop personalized treatments for patients with GN and identify new ways of detecting high-risk GN.
To do this, we will build upon an established research program to develop a collaborative national patient-centered program. We will expand a successful clinical database structure so it is available to the Canadian research community. We will study strategies for GN treatment that are tailored to a patient’s individual needs. We will look for specific genes and proteins that can help predict disease progression and whether an individual will benefit from innovative treatments.
Once the infrastructure is ready and the protocol approved, we will begin recruitment of 350 patients with GN. Patients enrolled in our study will be seen every six months for blood tests and updates regarding their health and well-being.
Canadian Glomerulonephritis Registry
Dr. Heather Reich
Click to view full size
Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes
American Journal of Kidney Diseases
Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI
Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes
Marcovecchio ML, Colombo M, Dalton RN, McKeigue PM, Benitez-Aguirre P, Cameron FJ, Chiesa ST, Couper JJ, Craig ME, Daneman D, Davis EA, Deanfield JE, Donaghue KC, Jones TW, Mahmud FH, Marshall SM, Neil A, Colhoun HM, Dunger DB; AdDIT and the SDRNT1BIO Investigators.
Comparison of Clinical and Social Characteristics of Canadian Youth Living with Type 2 and Type 1 Diabetes
Canadian Journal of Diabetes
Carino M, Elia Y, Sellers E, Curtis J, McGavock J, Scholey J, Hamilton J, Clarson C, Pinto T, Hadjiyannakis S, Mertens L, Samaan MC, Ho J, Nour M, Panagiotopoulos C, Jetha M, Gabbs M, Mahmud FH, Wicklow B, Dart A